Olivier Humbert1,2, Maud Lasserre2, Aurélie Bertaut3, Pierre Fumoleau4, Charles Coutant5, François Brunotte2,6,7, Alexandre Cochet2,6,7. 1. Department of Nuclear Medicine, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice, France ohumbert@unice.fr. 2. Department of Nuclear Medicine, Centre G.F. Leclerc, Dijon, France. 3. Department of Biostatistics, Centre G.F. Leclerc, Dijon, France. 4. Department of Medical Oncology, Centre G.F. Leclerc, Dijon, France. 5. Department of Surgery, Centre G.F. Leclerc, Dijon, France. 6. Imaging Department, CHU Le Bocage, Dijon, France; and. 7. Le2i FRE2005, CNRS, Arts et Métiers, Université Bourgogne Franche-Comté, Dijon, France.
Abstract
Early changes in tumor glucose metabolism (SUVmax) and in tumor blood flow (BF) have been evaluated separately for monitoring breast cancer response to neoadjuvant chemotherapy (NAC). This study used a single 18F-FDG dual-acquisition PET examination to simultaneously assess these two imaging features and to determine whether they correlate with the same pretherapy tumor phenotypic features and whether they are comparable or complementary in predicting pathologic complete response (pCR). Methods: This prospective study included 150 women with breast cancer and an indication for NAC. A 2-min chest-centered dynamic PET acquisition was performed at the time of 18F-FDG injection, followed by a delayed static PET acquisition 90 min later. Tumor BF was calculated from the dynamic acquisition using a validated first-pass model, and tumor SUVmax was calculated from the delayed acquisition. This dual acquisition was repeated after the first cycle of NAC to measure early changes in tumor BF and SUVmax Results: A weak correlation was found between SUVmax and BF at baseline (r = 0.22; P = 0.006). A high baseline SUVmax was associated with all biologic markers of tumor aggressiveness, including the triple-negative breast cancer subtype (P < 0.0001). In contrast, a high baseline BF was associated only with obesity (P = 0.002). The change in SUVmax (mean, -44.6% ± 27.4%) varied depending on the Scarff-Bloom-Richardson grade, overexpression of human epidermal growth factor receptor 2 (HER2-positive), and lack of hormone receptor expression (P = 0.04, P < 0.001, and P = 0.01, respectively). BF (mean change, -26.9% ± 54.3%) showed a drastic reduction only in HER2-positive subtypes (-58.7% ± 30.0%), supporting the antiangiogenic effect of trastuzumab. Changes in SUVmax outperformed changes in BF for predicting pCR in all tumor subtypes: the areas under the curve for change in SUVmax were 0.82, 0.65, and 0.90 in the triple-negative, HER2-positive, and luminal subtypes, respectively. Conclusion: Of the two biologic hallmarks of cancer evaluated in this study, a reduction in tumor glucose metabolism was more accurate than a reduction in tumor BF for predicting pCR in the different subtypes of breast cancer.
Early changes in tumor glucose metabolism (SUVmax) and in tumor blood flow (BF) have been evaluated separately for monitoring breast cancer response to neoadjuvant chemotherapy (NAC). This study used a single 18F-FDG dual-acquisition PET examination to simultaneously assess these two imaging features and to determine whether they correlate with the same pretherapy tumor phenotypic features and whether they are comparable or complementary in predicting pathologic complete response (pCR). Methods: This prospective study included 150 women with breast cancer and an indication for NAC. A 2-min chest-centered dynamic PET acquisition was performed at the time of 18F-FDG injection, followed by a delayed static PET acquisition 90 min later. Tumor BF was calculated from the dynamic acquisition using a validated first-pass model, and tumor SUVmax was calculated from the delayed acquisition. This dual acquisition was repeated after the first cycle of NAC to measure early changes in tumor BF and SUVmax Results: A weak correlation was found between SUVmax and BF at baseline (r = 0.22; P = 0.006). A high baseline SUVmax was associated with all biologic markers of tumor aggressiveness, including the triple-negative breast cancer subtype (P < 0.0001). In contrast, a high baseline BF was associated only with obesity (P = 0.002). The change in SUVmax (mean, -44.6% ± 27.4%) varied depending on the Scarff-Bloom-Richardson grade, overexpression of humanepidermal growth factor receptor 2 (HER2-positive), and lack of hormone receptor expression (P = 0.04, P < 0.001, and P = 0.01, respectively). BF (mean change, -26.9% ± 54.3%) showed a drastic reduction only in HER2-positive subtypes (-58.7% ± 30.0%), supporting the antiangiogenic effect of trastuzumab. Changes in SUVmax outperformed changes in BF for predicting pCR in all tumor subtypes: the areas under the curve for change in SUVmax were 0.82, 0.65, and 0.90 in the triple-negative, HER2-positive, and luminal subtypes, respectively. Conclusion: Of the two biologic hallmarks of cancer evaluated in this study, a reduction in tumor glucose metabolism was more accurate than a reduction in tumor BF for predicting pCR in the different subtypes of breast cancer.
Authors: William Stevens; Isabelle M Farrow; Leonidas Georgiou; Andrew M Hanby; Timothy J Perren; Laura M Windel; Daniel J Wilson; Nisha Sharma; David Dodwell; Thomas A Hughes; Barbara Jg Dall; David L Buckley Journal: Br J Radiol Date: 2021-06-09 Impact factor: 3.039